4.9589

0.10% -0.0111

Altimmune Inc (ALT)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

$4.97

Offen:

$4.97

24-Stunden-Volumen:

442.97K

Relative Volume:

0.19

Marktkapitalisierung:

$338.86M

Einnahmen:

$409.00K

Nettoeinkommen (Verlust:

$-101.35M

KGV:

-3.0237

EPS:

-1.64

Netto-Cashflow:

$-71.49M

1W Leistung:

+9.12%

1M Leistung:

-17.93%

6M Leistung:

-26.61%

1J Leistung:

-29.87%

1-Tages-Spanne:

$4.92

$5.0535

1-Wochen-Bereich:

$4.37

$5.225

52-Wochen-Spanne:

$3.553

$11.16

Altimmune Inc Stock (ALT) Company Profile

Firmenname

Altimmune Inc

Sektor

Healthcare (1155)

Branche

Biotechnology (679)

Telefon

(240) 654-1450

Adresse

910 CLOPPER ROAD, GAITHERSBURG, MD

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-11-05

Neueste SEC-Einreichungen

ALT's Discussions on Twitter

Vergleichen Sie ALT mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ALT Altimmune Inc	4.95	338.86M	409.00K	-101.35M	-71.49M	-1.64
VRTX Vertex Pharmaceuticals Inc	490.60	124.91B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	593.46	60.05B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	602.00	35.88B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	241.95	29.83B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	256.68	24.58B	3.81B	-644.79M	-669.77M	-6.24

Altimmune Inc Stock (ALT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-02-28	Eingeleitet	William Blair	Mkt Perform
2025-01-08	Eingeleitet	Stifel	Buy
2024-11-12	Eingeleitet	UBS	Buy
2024-04-29	Herabstufung	Guggenheim	Buy → Neutral
2024-01-24	Eingeleitet	Goldman	Neutral
2023-03-22	Herabstufung	Goldman	Buy → Neutral
2022-12-01	Eingeleitet	Goldman	Buy
2021-12-29	Fortgesetzt	Jefferies	Buy
2021-06-02	Eingeleitet	H.C. Wainwright	Buy
2021-02-11	Eingeleitet	Guggenheim	Buy
2020-12-14	Eingeleitet	Jefferies	Buy
2020-11-12	Bestätigt	B. Riley Securities	Buy
2020-09-25	Eingeleitet	B. Riley FBR	Buy
2020-08-14	Eingeleitet	Evercore ISI	Outperform
2020-07-31	Eingeleitet	Piper Sandler	Overweight
2020-07-28	Eingeleitet	JMP Securities	Mkt Outperform
2020-02-24	Fortgesetzt	ROTH Capital	Buy
2019-07-19	Eingeleitet	ROTH Capital	Buy
2017-10-09	Eingeleitet	Piper Jaffray	Overweight

Alle ansehen

Altimmune Inc Aktie (ALT) Neueste Nachrichten

Apr 20, 2025

Trading (ALT) With Integrated Risk Controls - news.stocktradersdaily.com

Apr 20, 2025

Apr 11, 2025

Nasal Vaccines Market Top Companies StudyVaxart, Inc, FluGen Inc, Altimmune, Inc, Sinovac Biotech Ltd. - openPR.com

Apr 11, 2025

Apr 10, 2025

Altimmune's US$42m Market Cap Fall Books Insider Losses - Yahoo

Apr 10, 2025

Apr 09, 2025

Coulter Partners places seasoned biopharmaceutical industry executives to Altimmune Board of Directors - Hunt Scanlon Media

Apr 09, 2025

Apr 08, 2025

Altimmune’s SWOT analysis: pemvidutide potential drives stock outlook By Investing.com - Investing.com Canada

Apr 08, 2025

Altimmune's SWOT analysis: pemvidutide potential drives stock outlook - Investing.com

Apr 08, 2025

Apr 06, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 06, 2025

Apr 04, 2025

H.C. Wainwright maintains Buy rating on Altimmune stock By Investing.com - Investing.com South Africa

Apr 04, 2025

H.C. Wainwright maintains Buy rating on Altimmune stock - Investing.com India

Apr 04, 2025

Apr 03, 2025

8 Analysts Assess Altimmune: What You Need To Know - Benzinga

Apr 03, 2025

Altimmune’s Pemvidutide: A Promising Catalyst with Blockbuster Potential and Strong Financial Backing - TipRanks

Apr 03, 2025

Altimmune Shares Sink This Year, But Retail Traders See A Buyout On The Horizon - MSN

Apr 03, 2025

Apr 02, 2025

JMP maintains Altimmune stock target at $25 on Phase 2b optimism - Investing.com

Apr 02, 2025

Mar 31, 2025

PharmAthene stock hits 52-week low at $5.1 amid challenges By Investing.com - Investing.com South Africa

Mar 31, 2025

PharmAthene stock hits 52-week low at $5.1 amid challenges - Investing.com

Mar 31, 2025